4-甲基-5-嘧啶甲酸乙酯 | 110960-73-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 酯类 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-甲基-5-嘧啶甲酸乙酯
• 中文别名: 4-甲基嘧啶-5-甲酸乙酯
• 英文名称: ethoxycarbonyl-5 methyl-4 pyrimidine
• 英文别名: 4-methyl-5-ethoxycarbonylpyrimidine；ethyl 4-methylpyrimidine-5-carboxylate
• CAS: 110960-73-1
• 化学式: C₈H₁₀N₂O₂
• 分子量: 166.18
• InChiKey: VVZGEVKJTLFQQS-UHFFFAOYSA-N

物化性质

• 沸点：
  74-78 °C(Press: 0.2 Torr)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 4-methylpyrimidine-5-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 4-methylpyrimidine-5-carboxylate
CAS number: 110960-73-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10N2O2
Molecular weight: 166.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基-5-嘧啶甲酸乙酯 在 水 、 sodium hydroxide 作用下， 以 水 、 丙酮 为溶剂， 反应 1.5h， 生成 1-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-3-(4-methylpyrimidin-5-yl)urea
  参考文献：
  名称：

  [EN] PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL
  [FR] DÉRIVÉS DE PYRAZOLE EN TANT QUE MODULATEURS DU CANAL CALCIQUE ACTIVÉ PAR LA LIBÉRATION DU CALCIUM

  摘要：

  公开号：

  WO2011042797A4
• 作为产物：
  描述：

  3-氨基巴豆酸乙酯 、 原甲酸三乙酯 在 ammonium acetate 、 zinc(II) chloride 作用下， 以 甲苯 为溶剂， 反应 5.0h， 以77%的产率得到4-甲基-5-嘧啶甲酸乙酯
  参考文献：
  名称：

  ZnCl 2催化三组分偶合反应的4,5-二取代嘧啶衍生物的前所未有的制备方法

  摘要：

  我们开发了ZnCl 2催化的三组分偶联反应，涉及多种官能化的烯胺，原甲酸三乙酯和乙酸铵，可在单个步骤中生产4,5-二取代的嘧啶衍生物。使用甲基酮衍生物代替烯胺，该方法可以成功地用于有效合成单取代和二取代的嘧啶衍生物。

  DOI：

  10.1021/ol900382j

文献信息

• NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL
  申请人：Muthuppalaniappan Meyyappan

  公开号：US20110105447A1

  公开（公告）日：2011-05-05

  Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

  本发明涉及一种新的钙释放激活钙（CRAC）通道抑制剂，以及制备它们的方法，包含它们的制药组合物和使用它们的治疗方法。本发明还涉及使用CRAC抑制剂治疗非小细胞肺癌（NSCLC）的方法，以及识别治疗和诊断癌症的治疗剂的方法。
• Modulators of calcium release-activated calcium channel
  申请人：Rhizen Pharmaceuticals SA

  公开号：US08921364B2

  公开（公告）日：2014-12-30

  Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

  本发明涉及一种新型的钙释放激活钙（CRAC）通道抑制剂，其制备方法，含有它们的制药组合物以及使用它们的治疗方法。本公开还涉及使用CRAC抑制剂治疗非小细胞肺癌（NSCLC）的方法，以及用于诊断和治疗癌症的治疗药物的识别方法。
• [EN] BENZOFURAN COMPOUNDS AS STING AGONISTS<br/>[FR] COMPOSÉS DE BENZOFURANE EN TANT QU'AGONISTES DE STING
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2022169921A1

  公开（公告）日：2022-08-11

  The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及式（I）和（II）的化合物，其中所有取代基的定义如本文所述，以及包括本发明化合物的药学上可接受的组合物和使用该组合物治疗各种疾病的方法。
• Bajnati, Abdelilah; Kokel, Bruno; Hubert-Habart, Michel, Bulletin de la Societe Chimique de France, 1987, # 2, p. 318 - 324
  作者：Bajnati, Abdelilah、Kokel, Bruno、Hubert-Habart, Michel

  DOI：——

  日期：——
• Two paths for the formation of pyrimidines from sym-triazine
  作者：S. P. Gromov、D. V. Yashunskii、R. S. Sagitullin、Yu. G. Bundel'

  DOI：10.1007/bf00531486

  日期：1992.9